- Letter to the Editor
- Open Access
Haploinsufficiency of Bcl11b suppresses the progression of ATM-deficient T cell lymphomas
Journal of Hematology & Oncology volume 8, Article number: 94 (2015)
Bcl11b is a transcription factor important for T cell development and also a tumor-suppressor gene that is hemizygously inactivated in ~10 % human T cell acute lymphoblastic leukemia (T-ALL) and several murine T-ALL models, including ATM−/− thymic lymphomas. Here we report that heterozygous loss of Bcl11b (Bcl11b+/−) unexpectedly reduced lethal thymic lymphoma in ATM−/− mice by suppressing lymphoma progression, but not initiation. The suppression was associated with a T cell-mediated immune response in ATM−/−Bcl11b+/− mice, revealing a haploid insufficient function of Bcl11b in immune modulation against lymphoma and offering an explanation for the complex relationship between Bcl11b status with T-ALL prognosis.
Bcl11b is a transcription factor that is “monoallelically” inactivated in ~10 % of human T cell acute lymphoblastic leukemia (T-ALL) [1–3] and several murine T-ALL models, including ATM−/− thymic lymphomas [4–6]. Both human and murine T-ALLs retain at least one intact copy of Bcl11b, indicating that Bcl11b is a bona fide haploinsufficient tumor-suppressor gene. Complete loss of the Bcl11b gene abrogates T cell development and gain of NK cell phenotype, revealing a critical role of Bcl11b in T cell lineage commitment [7–10]. Conditional inactivation of both copies of Bcl11b in double-positive (DP) T cells leads to overproduction of innate CD8+ single-positive (SP) T cells  and compromises T-regulatory cell function . Yet, hemizygous loss of Bcl11b has no measurable impact on T cell function [7–10] and the mechanism by which it promotes T-ALL remains elusive.
To address this, we characterized Bcl11b+/−ATM−/− mice [6, 13]. ATM kinase is a master regulator of the DNA damage responses . ATM−/− mice routinely succumb to immature T cell lymphomas sharing molecular features with human T-ALL. Of the ATM−/− thymic lymphomas, 80 % hemizygously deleted Bcl11b as a result of non-reciprocal t(12;14) translocation [6, 15]. Conditional inactivation of Bcl11b in T cells via LckCre eliminates recurrent t(12;14) translocations from ATM−/− thymic lymphomas, suggesting Bcl11b as the target of the large chromosome 12 deletion . ATM−/−Bcl11b+/− mice were born at expected frequency (Additional file 1: Figure S1A). Thymocyte development and peripheral T and B cell repertoire in young (4 week) ATM−/−Bcl11b+/− mice were indistinguishable from that of ATM−/− mice, displaying reduced surface TCRβ/CD3ε expression in DP cells and a partial blockade at the DP to SP transition characteristic for ATM-deficiency [6, 17] (Additional file 1: Figure S1B).
While we initially expected Bcl11b-deficiency to accelerate ATM-deficient thymic lymphomas based on its frequent inactivation in T-ALLs, hemizygous-deletion of Bcl11b prevented lethal thymic lymphoma in ~50 % ATM−/− mice and only 2/11 ATM−/−Bcl11b+/− mice developed overt thymic lymphomas (Fig. 1a). The median survival of ATM−/−Bcl11b+/− mice was significantly longer than that of ATM−/− controls (167 vs. 106 days, p < 0.01) (Fig. 1a). Analyses of 3- and 10-month-old ATM−/−Bcl11b+/− mice revealed clonal expansion of immature (surfaceTCRβlow) thymocytes in 3-month, but not 10-month-old ATM−/−Bcl11b+/− mice (Fig. 1b, c). T cell lymphomas from 3-month-old ATM−/−Bcl11b+/− mice retained both WT and null alleles of Bcl11b, consistent with the lack-of-LOH in T-ALL (Fig. 1d). Despite the clonal expansion in 3-month-old ATM−/−Bcl11b+/− mice, most thymic lymphomas failed to progress to lethal disease (Additional file 1: Figure S1C), suggesting that heterozygous Bcl11b-deficiency suppresses the progression, but not the initiation of ATM−/− thymic lymphomas.
Notably, almost all ATM−/−Bcl11b+/− mice developed variable degrees of splenomegaly, excessive submandibular lymph node (LN) enlargement that manifested to fatal airway obstruction (non-lymphoma-related death), and dermal inflammation commencing at 2–3 months of age (Fig. 2a). In contrast to normal lymphocyte profiles in 3-month-old ATM+/+(+/−)Bcl11b+/− mice (Additional file 1: Figure S2A and S2B), histologic analyses consistently revealed a lymphocyte-mediated inflammatory/immune disorder in ATM−/−Bcl11b+/− mice characterized by marked plasmacytosis with reactive germinal centers (B220+IgM+ Bcl6+CD138− B cells) in submandibular LN, reactive follicular hyperplasia of the white pulp and increased extramedullary hematopoiesis in the red pulp in the spleen (Fig. 2b and Additional file 1: Figure S2C), and acute and chronic dermal inflammation in the skin. While a cell-autonomous function of Bcl11b deletion on epidermal integrity cannot be ruled out , the splenic and LN changes noted raised the possibility of an autoimmune disorder, which could have contributed to the lack of tumor progression in ATM−/−Bcl11b+/− mice. Correspondingly, 10-month tumor-free ATM−/−Bcl11b+/− mice accumulated activated CD8+ T cell in PB (Fig. 2c).
Our data suggest that in an ATM-deficient background, heterozygous Bcl11b deficiency tilts immune homeostasis and limits the expansion, but not the initiation of ATM-deficient thymic lymphomas. Notably, homozygous Bcl11b deletion suppressed melanoma in murine models . Given the role of Bcl11b in T cell lineage commitment, CD8+ T cell development, and T-reg function, our data suggest that heterozygous Bcl11b deficiency can modulate anti-tumor immune response despite the lack of measurable T cell development defects in Bcl11b+/− mice [7–10]. This role of Bcl11b in immune modulation and tumor suppression might explain the discrepancies between Bcl11b status (mutation, deletion, and downregulation) and T-ALL prognosis in different studies [1–3, 19]. It also suggests that Bcl11b is likely lost later during T-ALL development, as early deletion likely causes autoimmune dysfunction, analogous to TNFAIP3 (A20) in DLBCL .
acute lymphoblastic leukemia
ataxia telangiectasia mutated
De Keersmaecker K, Real PJ, Gatta GD, Palomero T, Sulis ML, Tosello V, et al. The TLX1 oncogene drives aneuploidy in T cell transformation. Nat Med. 2010;16(11):1321–7.
Gutierrez A, Kentsis A, Sanda T, Holmfeldt L, Chen SC, Zhang J, et al. The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. Blood. 2011;118(15):4169–73.
Bartram I, Gokbuget N, Schlee C, Heesch S, Fransecky L, Schwartz S, et al. Low expression of T-cell transcription factor BCL11b predicts inferior survival in adult standard risk T-cell acute lymphoblastic leukemia patients. Journal of Hematology & Oncology. 2014;7:51.
Wakabayashi Y, Inoue J, Takahashi Y, Matsuki A, Kosugi-Okano H, Shinbo T, et al. Homozygous deletions and point mutations of the Rit1/Bcl11b gene in gamma-ray induced mouse thymic lymphomas. Biochem Biophys Res Commun. 2003;301(2):598–603.
Kamimura K, Ohi H, Kubota T, Okazuka K, Yoshikai Y, Wakabayashi Y, et al. Haploinsufficiency of Bcl11b for suppression of lymphomagenesis and thymocyte development. Biochem Biophys Res Commun. 2007;355(2):538–42.
Zha S, Bassing CH, Sanda T, Brush JW, Patel H, Goff PH, et al. ATM-deficient thymic lymphoma is associated with aberrant tcrd rearrangement and gene amplification. Journal of Experimental Medicine. 2010;207(7):1369–80.
Ikawa T, Hirose S, Masuda K, Kakugawa K, Satoh R, Shibano-Satoh A, et al. An essential developmental checkpoint for production of the T cell lineage. Science. 2010;329(5987):93–6.
Li L, Leid M, Rothenberg EV. An early T cell lineage commitment checkpoint dependent on the transcription factor Bcl11b. Science. 2010;329(5987):89–93.
Li P, Burke S, Wang J, Chen X, Ortiz M, Lee SC, et al. Reprogramming of T cells to natural killer-like cells upon Bcl11b deletion. Science. 2010;329(5987):85–9.
Wakabayashi Y, Watanabe H, Inoue J, Takeda N, Sakata J, Mishima Y, et al. Bcl11b is required for differentiation and survival of alphabeta T lymphocytes. Nat Immunol. 2003;4(6):533–9.
Hirose S, Touma M, Go R, Katsuragi Y, Sakuraba Y, Gondo Y, et al. Bcl11b prevents the intrathymic development of innate CD8 T cells in a cell intrinsic manner. International Immunology. 2014;27(4):205–15.
Vanvalkenburgh J, Albu DI, Bapanpally C, Casanova S, Califano D, Jones DM, et al. Critical role of Bcl11b in suppressor function of T regulatory cells and prevention of inflammatory bowel disease. J Exp Med. 2011;208(10):2069–81.
Golonzhka O, Liang X, Messaddeq N, Bornert JM, Campbell AL, Metzger D, et al. Dual role of COUP-TF-interacting protein 2 in epidermal homeostasis and permeability barrier formation. J Invest Dermatol. 2009;129(6):1459–70.
Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol. 2008;9(10):759–69.
Jiang W, Lee BJ, Li C, Dubois RL, Gostissa M, Alt FW, et al. Aberrant TCR rearrangement underlies the T-cell lymphocytopenia and t(12;14) translocation associated with ATM deficiency. Blood. 2015;125(17):2665–8.
Ehrlich LA, Yang-Iott K, Bassing CH. Tcrdelta translocations that delete the Bcl11b haploinsufficient tumor suppressor gene promote atm-deficient T cell acute lymphoblastic leukemia. Cell Cycle. 2014;13(19):3076–82.
Borghesani PR, Alt FW, Bottaro A, Davidson L, Aksoy S, Rathbun GA, et al. Abnormal development of Purkinje cells and lymphocytes in Atm mutant mice. Proc Natl Acad Sci USA. 2000;97(7):3336–41.
Uddin MN, Zhang Y, Harton JA, MacNamara KC, Avram D. TNF-alpha-dependent hematopoiesis following Bcl11b deletion in T cells restricts metastatic melanoma. J Immunol. 2014;192(4):1946–53.
Van Vlierberghe P, Ambesi-Impiombato A, De Keersmaecker K, Hadler M, Paietta E, Tallman MS, et al. Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia. Blood. 2013;122(1):74–82.
Ma A, Malynn BA. A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat Rev Immunol. 2012;12(11):774–85.
We thank Drs. Mark Leid and Adolfo A. Ferrando for generously sharing the Bcl11b deficient mouse models and discussing the experimental results. We thank Ms. Hongyan Tang and Dr. David Dominguez-Sola in the laboratory of Dr. Riccardo Dalla-Favera for the help with the histopathology analyses. We also wish to apologize to colleagues, whose work could not be cited due to space limitations. This work is in part supported by NIH/NCI R01CA158073, NIH/NCI R01CA184187, NIH/NIAID R21AI103826, and American Cancer Society Research Scholar Grant (RSG-13-038-01 DMC) to SZ and NIH/NCI 1P01CA174653-01 to both SZ and GB. SZ is the recipient of Leukemia Lymphoma Society Scholar Award. KP is a St Baldrick’s Fellow for Pediatric Cancer and WJ was in part supported by NIH/NCI T32-CA09503. All animal experiments were conducted within the guidelines of Columbia University Institution Animal Use and Care Committee (protocol number AAAF7653 and AAAJ3651).
WJ, KP, and SZ designed the experiments. KP, WJ, and SZ wrote the manuscript. GB performed the histopathologic analysis. KP, WJ, BJL, DGL, CL, and SZ performed the experiments.
The authors declare that they have no competing interests.
Kerice A. Pinkney and Wenxia Jiang contributed equally to this work.
Additional file 1: Figure S1.
Characterization of T cell development in ATM−/−Bcl11b+/− mice. (A) Actual and expected offspring from breeding between Bcl11b+/−ATM+/− and ATM+/− mice. The p value calculated based on chi-squared test is 0.89. (B) Representative flow cytometric analysis of pre-malignant thymocytes from WT, ATM−/− and ATM−/−Bcl11b+/− mice (4–6 weeks). Figure S2. Analyses of autoimmunity in ATM−/−Bcl11b+/− mice. (A) Flow cytometric analysis of the spleen, bone marrow, and lymph nodes from 3-month and 10-month-old ATM−/−Bcl11b+/− mice. Notably, the frequency of the CD11b+ myeloid cells increases in the spleen of ATM−/−Bcl11b+/− mice, consistent with increased extramedullary hematopoiesis in the red pulp seen in Fig. 2b. (B) Flow cytometric analyses of the thymus and spleen (SPL) from 3-month-old littermate ATM+/+Bcl11b+/+ (WT), Bcl11b+/−, ATM+/−Bcl11b+/− mice. Double negative (DN) staining was performed on gated CD8-CD4-CD19-TCRγ/δ− thymocytes. Homozygous deletion of Bcl11b dramatically increased the number of phenotypical NK cells [8, 9]. The percentage of NK1.1+ or CD8+ cells does not significantly increase in the thymus and spleen of 3-month-old Bcl11b+/− mice. (C) Immunohistochemical staining with germinal center marker Bcl6 and plasma cell marker CD138 of the enlarged submandibular lymph nodes. (PDF 2082 kb)
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Pinkney, K.A., Jiang, W., Lee, B.J. et al. Haploinsufficiency of Bcl11b suppresses the progression of ATM-deficient T cell lymphomas. J Hematol Oncol 8, 94 (2015). https://doi.org/10.1186/s13045-015-0191-8
- Reactive Germinal Center
- Submandibular Lymph Node
- Thymic Lymphoma
- Conditional Inactivation
- Cell Lineage Commitment